The maker of portable “phone booth” private rooms for offices now has a line of wheelchair accessible conference rooms.

Office romances are more common than most people think. Research shows how remote work contributes to these relationships and ...

Verve has implemented temporary salary reductions, expense and assistant overtime scrutiny amid belt-tightening in agency industry and beyond.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering better commercial prospects.

Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Is it too late to buy Verve Therapeutics stock? Usually, when an acquisition of a clinical-stage drugmaker is announced, investors don't have much incentive to buy the small biotech stock before ...

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a ...

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic ...